[{"address1": "1901 West 47th Place", "city": "Kansas City", "state": "KS", "zip": "66205", "country": "United States", "phone": "913 942 2300", "website": "https://www.cingulate.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Dr. Laurie A. Myers M.B.A., Ph.D.", "age": 66, "title": "Executive VP & COO", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 415167, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew N. Brams M.D.", "age": 59, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 244792, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.36, "open": 2.0, "dayLow": 1.28, "dayHigh": 2.0, "regularMarketPreviousClose": 3.36, "regularMarketOpen": 2.0, "regularMarketDayLow": 1.28, "regularMarketDayHigh": 2.0, "beta": -0.538, "forwardPE": -0.11515152, "volume": 2967619, "regularMarketVolume": 2967619, "averageVolume": 1601054, "averageVolume10days": 372020, "averageDailyVolume10Day": 372020, "bid": 1.4, "ask": 1.39, "bidSize": 1000, "askSize": 3100, "marketCap": 1928726, "fiftyTwoWeekLow": 1.28, "fiftyTwoWeekHigh": 38.6, "fiftyDayAverage": 4.95358, "twoHundredDayAverage": 12.298995, "currency": "USD", "enterpriseValue": 2864045, "floatShares": 864645, "sharesOutstanding": 1450170, "sharesShort": 115122, "sharesShortPriorMonth": 8962, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0794, "heldPercentInsiders": 0.26839, "heldPercentInstitutions": 0.06874, "shortRatio": 0.03, "shortPercentOfFloat": 0.09810001, "impliedSharesOutstanding": 1450170, "bookValue": -0.111, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -21205276, "trailingEps": -31.2, "forwardEps": -11.55, "lastSplitFactor": "1:20", "lastSplitDate": 1701302400, "enterpriseToEbitda": -0.144, "52WeekChange": -0.83366334, "SandP52WeekChange": 0.19340658, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CING", "underlyingSymbol": "CING", "shortName": "Cingulate Inc.", "longName": "Cingulate Inc.", "firstTradeDateEpochUtc": 1638973800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "bf898f9d-c1c1-3f31-9c96-a5b2c0f73dcd", "messageBoardId": "finmb_1674914781", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.33, "targetHighPrice": 35.0, "targetLowPrice": 8.0, "targetMeanPrice": 21.5, "targetMedianPrice": 21.5, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 1986313, "totalCashPerShare": 2.12, "ebitda": -19936746, "totalDebt": 3604148, "quickRatio": 0.354, "currentRatio": 0.506, "returnOnAssets": -1.20235, "returnOnEquity": -5.12812, "freeCashflow": -9646880, "operatingCashflow": -16678666, "financialCurrency": "USD", "trailingPegRatio": null}]